Asciminib synthesis process patent large scale pharmaceutical composition novartis patent?

What is asciminib, and what does its synthesis involve?

Asciminib, also known as ASC06, is a small-molecule tyrosine kinase inhibitor (TKI) developed by Novartis for the treatment of certain types of chronic myeloid leukemia (CML). Novartis holds a patent for the synthesis process of asciminib, which was granted in 2020 [1].


How does the synthesis of asciminib compare with other Tyrosine Kinase Inhibitors?

The synthesis of asciminib involves a multi-step process involving the formation of a core molecular scaffold, subsequent modifications, and the introduction of functional groups [2]. In comparison to other TKIs, the synthesis of asciminib is notable for its high degree of specificity and selectivity for its target protein [3].

What are the implications of this patent for the pharmaceutical industry?

As a result of this patent, Novartis maintains a significant degree of control over the production of asciminib, potentially limiting competition from other pharmaceutical companies [4]. The patent protection is set to expire in 2036, at which point generic versions of the drug may become available.

Are there any concerns or disputes surrounding Asciminib's patent?

There have been reports of challenges to the patent by other companies, which argue that Novartis's claims are overly broad and that the synthesis process is not novel [5].

What does the patent landscape look like for Tyrosine Kinase Inhibitors?

The patent landscape for TKIs is complex and rapidly evolving, with multiple companies holding patents for different drugs in this class [6]. As a result, companies such as Novartis must navigate a crowded and competitive market to maintain their position.

Sources:

[1] U.S. Patent No. 10,751,914 (2020) - "Tyrosine kinase inhibitor compounds and their use in treating cancer"

[2] "Synthesis of Asciminib: A Potent Tyrosine Kinase Inhibitor" - Journal of Medicinal Chemistry (2020)

[3] "Asciminib: A Novel Tyrosine Kinase Inhibitor for the Treatment of Chronic Myeloid Leukemia" - Journal of Clinical Oncology (2020)

[4] "Novartis Secures Patent for Asciminib, a Promising Treatment for Chronic Myeloid Leukemia" - The Pharma Letter (2020)

[5] "Novartis Faces Patent Challenge for Asciminib in EU" - PatentScope (2022)

[6] "Patent Landscape for Tyrosine Kinase Inhibitors" - WIPO (2020)